These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36669559)

  • 21. Towards promising antimicrobial alternatives: The future of bacteriophage research and development in Saudi Arabia.
    Alsaadi A; Imam M; Alghamdi AA; Alghoribi MF
    J Infect Public Health; 2022 Dec; 15(12):1355-1362. PubMed ID: 36332378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
    Yeh TK; Jean SS; Lee YL; Lu MC; Ko WC; Lin HJ; Liu PY; Hsueh PR
    Int J Antimicrob Agents; 2022 Jan; 59(1):106475. PubMed ID: 34767917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?
    Hesse S; Adhya S
    Annu Rev Microbiol; 2019 Sep; 73():155-174. PubMed ID: 31185183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection.
    Ferry T; Kolenda C; Briot T; Souche A; Lustig S; Josse J; Batailler C; Pirot F; Medina M; Leboucher G; Laurent F; On Behalf Of The Lyon Bji Study Group ; On Behalf Of The PHAGEinLYON Study Group
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European regulatory aspects of phage therapy: magistral phage preparations.
    Verbeken G; Pirnay JP
    Curr Opin Virol; 2022 Feb; 52():24-29. PubMed ID: 34801778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective.
    Bessems L; Chen B; Uyttebroek S; Devolder D; Lood C; Verwimp S; De Munter P; Debaveye Y; Depypere M; Spriet I; Van Gerven L; Dupont L; Wagemans J; van Noort V; Lavigne R; Metsemakers WJ; Onsea J
    Front Cell Infect Microbiol; 2024; 14():1434397. PubMed ID: 39290977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory.
    Caflisch KM; Patel R
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31092596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections.
    Patey O; McCallin S; Mazure H; Liddle M; Smithyman A; Dublanchet A
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30597868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (
    Onsea J; Uyttebroek S; Chen B; Wagemans J; Lood C; Van Gerven L; Spriet I; Devolder D; Debaveye Y; Depypere M; Dupont L; De Munter P; Peetermans WE; van Noort V; Merabishvili M; Pirnay JP; Lavigne R; Metsemakers WJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.
    Leitner L; Ujmajuridze A; Chanishvili N; Goderdzishvili M; Chkonia I; Rigvava S; Chkhotua A; Changashvili G; McCallin S; Schneider MP; Liechti MD; Mehnert U; Bachmann LM; Sybesma W; Kessler TM
    Lancet Infect Dis; 2021 Mar; 21(3):427-436. PubMed ID: 32949500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of bone and periprosthetic infections with bacteriophages : A systematic review].
    Walter N; Deng L; Brochhausen C; Alt V; Rupp M
    Orthopade; 2022 Feb; 51(2):138-145. PubMed ID: 34499212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
    Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy.
    Segall AM; Roach DR; Strathdee SA
    Curr Opin Microbiol; 2019 Oct; 51():46-50. PubMed ID: 31226502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriophage therapy for
    Bhargava K; Nath G; Dhameja N; Kumar R; Aseri GK; Jain N
    Future Microbiol; 2023 Apr; 18():323-334. PubMed ID: 37140267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage Therapy as a Protective Tool Against Pathogenic Bacteria: How Far We Are?
    Singh K; Biswas A; Chakrabarti AK; Dutta S
    Curr Pharm Biotechnol; 2023; 24(10):1277-1290. PubMed ID: 36503459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions for necrotizing soft tissue infections in adults.
    Hua C; Bosc R; Sbidian E; De Prost N; Hughes C; Jabre P; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2018 May; 5(5):CD011680. PubMed ID: 29851032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfersomal Phage Cocktail Is an Effective Treatment against Methicillin-Resistant Staphylococcus aureus-Mediated Skin and Soft Tissue Infections.
    Chhibber S; Shukla A; Kaur S
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacteriophage Treatment: Critical Evaluation of Its Application on World Health Organization Priority Pathogens.
    Al-Ishaq RK; Skariah S; Büsselberg D
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33396965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacteriophage therapy: a regulatory perspective.
    Pelfrene E; Willebrand E; Cavaleiro Sanches A; Sebris Z; Cavaleri M
    J Antimicrob Chemother; 2016 Aug; 71(8):2071-4. PubMed ID: 27068400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.